Manufacturer: Signature Pharma
Pharmaceutical name: Orlistat
Pack: 21 cap (120 mg)
Orligal blocks some dietary fat, preventing it from being absorbed by your body. It is intended to be used alongside a reduced-calorie diet and weight management to address obesity in individuals with certain risk factors, such as diabetes, high blood pressure, and elevated cholesterol or triglycerides.
Orligal may also be prescribed for other uses not specified in this medication guide. Avoid taking Orligal if you are allergic to Orlistat or if you have gallbladder issues or chronic malabsorption syndrome (the inability to absorb food and nutrients properly). Prior to using Orligal, inform your doctor if you have an underactive thyroid, a history of gallstones or pancreatitis, type 1 or type 2 diabetes, an eating disorder, liver disease, or if you are taking other weight-loss medicines (either prescription or over-the-counter).
Do not administer over-the-counter Orlistat to a child under 18 years of age. Orligal should not be used by individuals aged 12 to 18 without a doctor's guidance. It should be used solely by the person for whom it is prescribed or recommended and must not be shared with anyone else, particularly those with a history of eating disorders. Keep Orligal stored in a location that is inaccessible to others.
Orligal is just one component of a comprehensive treatment plan that includes diet, exercise, and weight management. Your daily intake of fats, proteins, and carbohydrates should be evenly distributed across all meals. Adhere closely to your dietary, medicinal, and exercise regimens. While taking Orligal, avoid a high-fat diet. Consuming high-fat meals along with Orligal may heighten your risk of experiencing unpleasant gastrointestinal side effects.
Common side effects include headache, oily leakage from the rectum, abdominal discomfort or pain, flatulence (gas), sometimes accompanied by discharge, oily or fatty stools, an urgent or increased need for bowel movements, diarrhea, and low blood sugar levels (hypoglycemia) in individuals with type 2 diabetes.